Compare TEAM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEAM | VTRS |
|---|---|---|
| Founded | 2002 | 1961 |
| Country | Australia | United States |
| Employees | N/A | 30000 |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 18.7B |
| IPO Year | 2015 | 2019 |
| Metric | TEAM | VTRS |
|---|---|---|
| Price | $154.21 | $16.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $169.18 | $13.50 |
| AVG Volume (30 Days) | 5.0M | ★ 10.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 15.52 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $5,215,304,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $24.65 | $4.41 |
| Revenue Next Year | $17.67 | $1.96 |
| P/E Ratio | ★ N/A | $325.60 |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $56.01 | $9.43 |
| 52 Week High | $180.24 | $18.39 |
| Indicator | TEAM | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 80.31 | 39.70 |
| Support Level | $139.70 | $15.82 |
| Resistance Level | $166.48 | $16.54 |
| Average True Range (ATR) | 6.83 | 0.54 |
| MACD | 6.30 | -0.20 |
| Stochastic Oscillator | 99.27 | 4.20 |
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.